SCHEMBL3304418

SCHEMBL3304418

CCOC(=O)C1(NC(=O)c2cc(Cl)cc(Cl)c2O)Cc2ccccc2C1

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
STK39 Q9UEW8 7/20 0.42
CXCR5 P32302 8/20 0.42
ACLY P53396 1/20 0.41
PARG Q86W56 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3306335 0.90 CXCR5 (0.52) STK39CXCR5ACLYPARG
SCHEMBL3307319 0.88 CXCR5 (0.51) CXCR5
SCHEMBL3308370 0.82 CXCR5 (0.41) CXCR5
SCHEMBL3305632 0.81 CXCR5 (0.57) CXCR5
SCHEMBL3312127 0.80 CXCR5 (0.51) CXCR5
SCHEMBL3308741 0.79 CXCR5 (0.62) CXCR5
SCHEMBL3311839 0.79 CXCR5 (0.55) CXCR5ACLY
SCHEMBL3310224 0.78 CXCR5 (0.53) CXCR5
SCHEMBL3307161 0.77 CXCR5 (0.50) CXCR5
SCHEMBL3308192 0.77 CXCR5 (0.47) CXCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569535-B2 Substituted benzoylamino-indan-2-carboxylic acids and related compounds SANOFI (FR) 2013-10-29 US disclosed
US-20100113462-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
EP-2155711-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS Sanofi-Aventis (FR) 2010-02-24 EP disclosed
WO-2008151211-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113462-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS CXCR5, CXCR1, CCR5 STK39 2866/4885CXCR5 1/4885ACLY 3375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.